BIMINI Biotech has received a MIT feasibility grant (€20.000) for the ONCO-ID project. The Mkb-innovatiestimulering Regio en Topsectoren (MIT) stimulates innovation in small and medium-sized enterprises across regional borders. In addition, MIT encourages SME projects to better align with the knowledge and innovation agendas of the Missions for the future. This enables companies to carry…
Lees meer
Leiden, 26 November 2020 – BIMINI Biotech, an innovative therapeutics startup that develops new cancer drugs, has secured an investment of €200,000 from proof-of-concept fund UNIIQ to further develop its technology. The company aims to use the growth hormone receptor to uniquely inhibit cancer cell growth. The investment was announced digitally by Ida Haisma, director…
Lees meer
BIMINI Biotech is one of the 10 winners of the Academic Startup Competition 2020 and is now entitled to use the title ‘Best Academic Startup of 2020’ for the coming year. The other winning startups are DeNoize, Digi Bio, IamFluidics, Kaminari Medical, Lusoco, NC Biomatrix, Taylor, uCrowds and VanBoven. BIMINI Biotech develops innovative therapeutics in…
Lees meer
BIMINI Biotech has been nominated from no fewer than an astounding 57 contenders, by the Association of Universities in the Netherlands (Vereniging van Universiteiten (VSNU), the Netherlands Academy of Technology and Innovation (AcTI) and Techleap as one of the 20 academic startups to compete in the finals of the second edition of the Academic Startup…
Lees meer
BIMINI Biotech has been awarded the Eureka INNOWIDE grant of €60.000 to set up a collaborative (pre-) clinical network of expert parties in India and accelerate cost-effective drug development. Together with our expert partner TheraIndx, we will make these initial steps for our lead compound. As such, BIMINI aims to create a global impact. The…
Lees meer
BIMINI Biotech moved to the PLNT centre for innovation and entrepreneurship in Leiden, thereby joining the largest life sciences cluster in the Netherlands. From this new location, we are in the perfect position to progress our pre-clinical activities on our lead compounds for cancer towards the clinic. We are happy to welcome you in our…
Lees meer
BIMINI Biotech has been awarded the NWO Take-off Phase 1 grant (€40.000) in collaboration with the Universitair Medisch Centrum Utrecht (UMCU) to perform an extensive feasibility study for BIMINI’s lead compound. The aim of the grant is to stimulate entrepreneurship and valorisation of breakthrough innovations that originate from Dutch Universities. This grant will help BIMINI…
Lees meer
BIMINI Biotech is the proud winner of the LSW Venture Challenge. Over the course of three months, we have been working hard on the business case of our breakthrough innovation – a novel cure for triple negative breast cancer. Now, we aim to accelerate the development of our lead compound to bring it to the…
Lees meer
On November 28th, 2019 BIMINI will be present at the 15th edition of the Dutch Life Sciences conference that takes place at the Leiden Bio Science Park, CORPUS Congress Centre. BIMINI will participate in the investor forum pitch sessions and we will pitch our breakthrough idea in 1 minute during the award sessions of the venture challenge. We…
Lees meer
November 2019 – BIMINI Biotech is participating in the LifeSciences@Work Accelerator Venture challenge. The Venture Challenge is a 10-week programme to develop an initial idea – a breakthrough research result – into a solid business case. We are happy to take on this challenge and define the optimal route to success for our company.